Will the FDA approve any psychedelic substance for medical use before 2028?
8.0 pts (24h)Health & MedicineOne-Off1y
KalshiCheck availabilityKYC requiredVerified resolution dataWell calibratedSelected book midpoint
Yes · —
Loading selected book…
—
Stored price
Yes 69.5%
Yes 69.5%Market quality
26 / 100
Low quality24h Volume
$7
Open interest
$41.3
Low open interestBid / Ask
— / —
YesSpread
—
Market data
Updated 59 minutes ago
LaggingOct 21, 26, 4:00 PM UTCJan 1, 28, 4:59 AM UTC
Chart and changes show stored historical probabilities, not the selected live book.
Trends
Selected row: book midpoint. Other rows: stored references, possibly normalized; 24h changes use stored history.
Venue terms
Source: Kalshi
Informational venue terms only; CoinRithm paper trading uses its own rules.
- Early close:
- Yes
- Settlement timer:
- 30m (informational)
Market depth · Yes
Loading selected book…
—
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Will the FDA approve any psychedelic substance for medical use this year?
KalshiWill a psychedelic substance get de-scheduled by the US by 2030?
Manifold MarketsWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsWill the FDA approve the skin cancer vaccine by which date?
FutuurRules
This outcome's exact rule is not available.
- Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca. Important information: For purposes of this Contract: The listed substances are illustrative, not exhaustive. Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion. "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product. Complete Response Letters, tentative approvals, Emergency Use Authorizations, expanded access or compassionate use authorizations, and approvals limited to export do not satisfy the Payout Criterion. Combination products. Approval of a combination drug product satisfies the Payout Criterion only if at least one active ingredient is a listed (or otherwise qualifying) psychedelic substance and that psychedelic active ingredient has not previously been approved by the FDA via NDA or BLA for any human medical indication. By way of example, an FDA approval of AXS-05 (a combination of dextromethorphan and bupropion) for a new indication does not satisfy the Payout Criterion, because both active ingredients were FDA-approved prior to Issuance. New indications for previously-approved substances. An FDA approval (including via supplemental NDA or supplemental BLA) of a new medical indication, dosage, or formulation for a substance whose active pharmaceutical ingredient was already approved by the FDA via NDA or BLA prior to Issuance does not satisfy the Payout Criterion.
Rules for each outcome
- Yes
- This outcome's exact rule is not available.
- No
- This outcome's exact rule is not available.
